Integral Diagnostics Limited reaffirmed earnings guidance for the fiscal year of 2018. The company reaffirmed its guidance advised to the market on 12 January 2018, which included that it will achieve normalised fiscal year 2018 NPAT growth of around 20% (before takeover response costs and transaction costs). The company also reaffirmed the EBITDA guidance for fiscal year 2018 of $38 million to $39 million as disclosed in the company's 2 March 2018 Target's Statement.